Literature DB >> 2904568

Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.

B J Marshall1, C S Goodwin, J R Warren, R Murray, E D Blincow, S J Blackbourn, M Phillips, T E Waters, C R Sanderson.   

Abstract

100 consecutive patients with both duodenal ulcer and Campylobacter pylori infection were followed up to see whether eradication of C pylori affected ulcer healing or relapse. Patients were randomly assigned to 8 weeks of treatment with cimetidine or colloidal bismuth subcitrate (CBS), with tinidazole or placebo being given concurrently from days 1 to 10, inclusive. Endoscopy, biopsy, and culture were done at entry, in weeks 10, 22, 34, and 62, and whenever symptoms recurred. There was no maintenance therapy. C pylori persisted in all of the cimetidine-treated patients and in 95% of those treated with cimetidine/tinidazole, but was eradicated in 27% of the CBS/placebo group and 70% of the CBS/tinidazole group. When C pylori persisted, 61% of duodenal ulcers healed and 84% relapsed. When C pylori was cleared 92% of ulcers healed (p less than 0.001) and only 21% relapsed during the 12 month follow-up period (p less than 0.0001).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2904568     DOI: 10.1016/s0140-6736(88)90929-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  210 in total

Review 1.  Presentation and management of Helicobacter pylori infection in childhood.

Authors:  U Blecker; N K Mittal; D I Mehta
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

2.  Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin 1beta.

Authors:  T Watanabe; K Higuchi; K Tominaga; Y Fujiwara; T Arakawa
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

3.  Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study.

Authors:  S K Lam; C K Ching; K C Lai; B C Wong; C L Lai; C K Chan; L Ong
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

4.  In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.

Authors:  J K Akada; M Shirai; K Fujii; K Okita; T Nakazawa
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

5.  Effects of Helicobacter pylori infection on gastric acid secretion and serum gastrin levels in Mongolian gerbils.

Authors:  M Takashima; T Furuta; H Hanai; H Sugimura; E Kaneko
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

6.  Modification of a mammalian cell protein in the presence of [32P-adenylate]NAD: evidence for ADP ribosylation activity associated with Helicobacter pylori.

Authors:  Carlos W Nossa; Steven R Blanke
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 7.  Role of Helicobacter pylori in duodenal ulcer.

Authors:  E A Rauws
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

8.  Nonsteroidal anti-inflammatory drugs and ulcers.

Authors:  A H Soll
Journal:  West J Med       Date:  1992-10

9.  Upper gastrointestinal endoscopy in Malawi: an opportunity.

Authors:  Will Howson
Journal:  Malawi Med J       Date:  2010-12       Impact factor: 0.875

10.  No additive effect between Helicobacter pylori infection and portal hypertensive gastropathy on inducible nitric oxide synthase expression in gastric mucosa of cirrhotic patients.

Authors:  Usama A Arafa; Yasuhiro Fujiwara; Kazuhide Higuchi; Masatsugu Shiba; Toshiyuki Uchida; Toshio Watanabe; Kazunari Tominaga; Nobuhide Oshitani; Takayuki Matsumoto; Tetsuo Arakawa
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.